Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.

Literature DB >> 24342639

In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.

Xiaojuan Wang¹, Feifei Zhang, Chunjiang Zhao, Zhanwei Wang, Wright W Nichols, Raymond Testa, Henan Li, Hongbin Chen, Wenqiang He, Qi Wang, Hui Wang.

Abstract

Ceftazidime-avibactam, aztreonam-avibactam, and comparators were tested by reference broth microdilution against 372 nonrepetitive Gram-negative bacilli (346 unselected plus 26 selected meropenem-nonsusceptible Enterobacteriaceae isolates) collected from 11 teaching hospitals in China in 2011 and 2012. Meropenem-nonsusceptible isolates produced extended-spectrum β-lactamases (ESBLs; e.g., CTX-M-14/3), AmpCs (e.g., CMY-2), and/or carbapenemases (e.g., KPC-2 and NDM-1). Avibactam potentiated the activity of ceftazidime against organisms with combinations of ESBLs, AmpCs, and KPC-2. Aztreonam-avibactam was active against all β-lactamase producers (including producers of NDM-1 and IMP-4/8) except blaOXA-containing Acinetobacter baumannii and some Pseudomonas aeruginosa isolates.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 24342639 PMCID： PMC3957831 DOI： 10.1128/AAC.02123-13

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Authors: A Walkty; M DeCorby; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal: Antimicrob Agents Chemother Date: 2011-03-21 Impact factor: 5.191

Review 2. Carbapenemases: the versatile beta-lactamases.

Authors: Anne Marie Queenan; Karen Bush
Journal: Clin Microbiol Rev Date: 2007-07 Impact factor: 26.132

3. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae.

Authors: David M Livermore; Shazad Mushtaq; Marina Warner; Jiancheng Zhang; Sunil Maharjan; Michel Doumith; Neil Woodford
Journal: Antimicrob Agents Chemother Date: 2010-11-01 Impact factor: 5.191

4. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.

Authors: Andrea Endimiani; Yuvraj Choudhary; Robert A Bonomo
Journal: Antimicrob Agents Chemother Date: 2009-06-15 Impact factor: 5.191

5. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.

Authors: Jared L Crandon; David P Nicolau
Journal: Antimicrob Agents Chemother Date: 2013-05-06 Impact factor: 5.191

Review 6. Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics.

Authors: C C Sanders
Journal: Annu Rev Microbiol Date: 1987 Impact factor: 15.500

7. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Authors: P R S Lagacé-Wiens; F Tailor; P Simner; M DeCorby; J A Karlowsky; A Walkty; D J Hoban; G G Zhanel
Journal: Antimicrob Agents Chemother Date: 2011-02-28 Impact factor: 5.191

8. Cloning, sequence analyses, expression, and distribution of ampC-ampR from Morganella morganii clinical isolates.

Authors: L Poirel; M Guibert; D Girlich; T Naas; P Nordmann
Journal: Antimicrob Agents Chemother Date: 1999-04 Impact factor: 5.191

Review 9. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors.

Authors: Ken Coleman
Journal: Curr Opin Microbiol Date: 2011-08-11 Impact factor: 7.934

10. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors: Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal: J Antimicrob Chemother Date: 2009-06-02 Impact factor: 5.790

36 in total

1. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.

Authors: Shawn Vasoo; Scott A Cunningham; Nicolynn C Cole; Peggy C Kohner; Sanjay R Menon; Kevin M Krause; Kelly A Harris; Partha P De; Tse Hsien Koh; Robin Patel
Journal: Antimicrob Agents Chemother Date: 2015-09-21 Impact factor: 5.191

2. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.

Authors: James A Karlowsky; Krystyna M Kazmierczak; Boudewijn L M de Jonge; Meredith A Hackel; Daniel F Sahm; Patricia A Bradford
Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191

3. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors: Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191

Review 4. Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.

Authors: Ritu Banerjee; Romney Humphries
Journal: Virulence Date: 2016-05-11 Impact factor: 5.882

5. The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model.

Authors: S S Bhagwat; H Periasamy; S S Takalkar; S R Palwe; H N Khande; M V Patel
Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191

6. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.

Authors: James A Karlowsky; Douglas J Biedenbach; Krystyna M Kazmierczak; Gregory G Stone; Daniel F Sahm
Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.191

Review 7. Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors: Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal: Clin Pharmacokinet Date: 2019-05 Impact factor: 6.447